-
March 2018
StemBioSys Publishes Guest Article on Biotechnology Blog The Cell Culture Dish
StemBioSys Senior Scientist Travis Block published a guest article on the biotechnology blog The Cell Culture Dish. In it, he describes the benefits to researchers in using the CELLvo Endothelial Progenitor Cells. Click here to read the full article on Cell Culture Dish or continue reading below. Introduction to Endothelial Progenitor Cells Endothelial cells from the […]
-
February 2018
New branding identity and expanded product line announced by StemBioSys, Inc.
SAN ANTONIO – StemBioSys Inc. announced today a new branding identity for its cell research products and two new products that are the first to be marketed under the new brand name. StemBioSys’s products for the research market will be marketed under the brand name CELLvo™. StemBioSys has developed a marketing message that its product […]
-
December 2017
StemBioSys Announces New European Distributor For Stem Cell Research Products
SAN ANTONIO – StemBioSys Inc. announced today that it has entered into an agreement with Caltag Medsystems Ltd. to distribute and market StemBioSys products. Caltag will distribute StemBioSys products in the European Union. Initially, the agreement will cover StemBioSys’ cell expansion products, but as additional products are added to StemBioSys’ portfolio in the future, these […]
-
September 2017
StemBioSys Expands Its Footprint Into Houston
SAN ANTONIO – StemBioSys Inc. announced today that it will add a second office location. StemBioSys’s new location in Houston will be located in Johnson & Johnson Innovation, JLABS (JLABS) at the Texas Medical Center (JLABS @ TMC). JLABS is a life science innovation center, providing a flexible environment for start-up companies pursuing new technologies and research platforms to […]
-
March 2017
StemBioSys Licenses Additional Technology From UT Health San Antonio To Expand Existing Portfolio on Stem Cell-Enabling Technologies
SAN ANTONIO – StemBioSys Inc. announced today that it has licensed additional technology from UT Health™ San Antonio that expands the company’s intellectual property portfolio aimed at enabling the expansion of adult stem cells for therapeutic use. To date StemBioSys has converted three pending patents originally licensed from UT Health™ San Antonio into eight issued […]